Mark A. Velleca, M.D., Ph.D., born in 1973, is the current CEO of Black Diamond Therapeutics, Inc., a biotech firm he joined in September 2023. His background is impressive, with a medical degree and Ph.D. from Washington University in St....

Mark A. Velleca, M.D., Ph.D., born in 1973, is the current CEO of Black Diamond Therapeutics, Inc., a biotech firm he joined in September 2023. His background is impressive, with a medical degree and Ph.D. from Washington University in St. Louis. He has a rich history in the biotech world, including previous roles as CEO of G1 Therapeutics from 2014 to 2021 and as a senior advisor to major companies like Gilead Sciences. Dr. Velleca has been part of the board at Black Diamond since 2021, becoming its Chair in December 2022. His leadership track record shows a focus on achieving corporate goals and managing complex projects in drug development. Interestingly, he recently resigned from the Board of G1 Therapeutics but continues to work closely with the company as a senior advisor until the end of 2024. This reflects his strong commitment and influence within the biotech field, proving that his expertise is highly valued. In 2023, he earned about $1.18 million, combining salary and bonuses, showing how his performance is closely tied to the company’s success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Black Diamond Therapeutics, Inc. CEOs

B

Mark A. Velleca, M.D., Ph.D.

CEO of Black Diamond Therapeutics, Inc.

Education

M.D. and Ph.D. from Washington University in St. Louis

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1973 - 52 years ago

CEO of Black Diamond Therapeutics, Inc. for

1 year 8 months (Sep 2023 - Present)

Previous Experience

Former CEO of G1 Therapeutics, Inc.

Rivals

Competitors/colleagues of Mark A. Velleca, M.D., Ph.D.

Holdings

See how much did Mark A. Velleca, M.D., Ph.D. make over time.

Dr. Velleca's holdings in Black Diamond Therapeutics reflect his significant stake and involvement in the company. As of 2023, he was granted stock options for 1 million shares, aligning his interests with the company's performance. His trading activity shows fluctuations...

Dr. Velleca's holdings in Black Diamond Therapeutics reflect his significant stake and involvement in the company. As of 2023, he was granted stock options for 1 million shares, aligning his interests with the company's performance. His trading activity shows fluctuations with major trades around $2.88M in September 2022 and consistent selling in 2023, indicating strategic decisions in response to market conditions. Throughout 2023, he engaged in trading valued at approximately $10.5 million over the year, with the highest monthly trade peaking at $8.59M in September. This suggests that Dr. Velleca aims to capitalize on market opportunities while maintaining a significant position in the company he leads. Evaluating his trading history gives a glimpse into his financial strategies and confidence in the company's trajectory.

Loading...

Total Stock Sold

$6.29M

GTHX

$6.29M

386,040 GTHX shares

What if they kept their stock?

If Mark A. Velleca, M.D., Ph.D. didn't sell their stock, today they would have:
Extra GTHX386,040 shares worth $6.79M.
This is 7.94% and $499.84K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Mark A. Velleca, M.D., Ph.D..

GTHX

$120.56K

GTHX at $2.01/share

Aug 8, 2023

Sale

GTHX

$175.49K

GTHX at $11.70/share

Oct 18, 2022

Sale

GTHX

$270.04K

GTHX at $13.50/share

Sep 20, 2022

Sale

GTHX

$1.01M

GTHX at $12.64/share

Aug 16, 2022

Sale

GTHX

$570.26K

GTHX at $19.01/share

Jul 13, 2021

Sale

GTHX

$659.02K

GTHX at $21.97/share

Jun 15, 2021

Sale

GTHX

$597.10K

GTHX at $19.90/share

May 11, 2021

Sale

GTHX

$733.77K

GTHX at $24.46/share

Apr 13, 2021

Sale

GTHX

$983.48K

GTHX at $31.68/share

Feb 16, 2021

Sale

GTHX

$630.29K

GTHX at $21.01/share

Jan 19, 2021

Sale

Compensation History

See how much did Mark A. Velleca, M.D., Ph.D. make over time.

In 2023, Dr. Velleca's total compensation was about $1.18 million, comprised of a $620,000 salary and performance-based bonuses. His bonus was tied to corporate goals, rewarding his ability to deliver results. Interestingly, he emphasizes performance in his compensation philosophy, which means that if the company does well, he benefits directly. His prior roles show a trend of performance-based pay, where bonuses reflected his company's success. Moreover, Dr. Velleca previously earned over $900,000 in 2020, showing his earnings have varied based on company performance and market strategies. What stands out is his commitment to aligning his compensation with the achievement of specific targets set by the board. This approach not only incentivizes him but also assures stakeholders that he is focused on generating value for the company and its investors.

Year

2023

Total Compensation

$244.28K

Salary

$180.33K

Board Justification

The compensation philosophy is based on a pay-for-performance model, aligning executive compensation with company performance and market benchmarks.

Bonus

$0.00

Board Justification

No bonus was awarded for 2023 as the CEO position was held for part of the year only.

Other

$63.95K

Board Justification

This includes a 401(k) matching contribution and a $6,000 annual stipend for personal expenses.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the stock options granted were not specified to have vested during the year.

Performance Metrics

Performance metrics for determining compensation include corporate goals related to financial and operational measures.

Other Black Diamond Therapeutics, Inc. CEOs

Here are other CEOs of Black Diamond Therapeutics, Inc.

David M. Epstein, Ph.D.

Ex-CEO of Black Diamond Therapeutics, Inc.

January 2020 - September 2023